科创板开启IPO 注册制大门，企业盈利门槛桎梏打破：科创板上市要求较原A 股有较大变化。主要体现在，（1）科创板侧重于战略新兴产业，重视上市企业的行业属性。新一代信息技术、高端装备、新材料、新能源、节能环保以及生物医药等高新技术产业和战略性新兴产业被重点关注；（2）科创板发行条件放宽了盈利条件的限制。将市值作为核心指标，同时允许VIE 架构、红筹公司发行股票或发行存托凭证上市；（3）企业研发投入被纳入重要参考指标；（4）交易所审核为主，审核周期显著缩短。上市速度加快，目前上交所已经开始接收申请材料，最快下半年可以确定第一批上市企业；（5）将定价权交给市场，重视长期投资者。征求意见稿取消直接定价而采用市场化询价方式，并且将询价对象限制为公募基金、证券公司、保险公司等7 类机构投资者；此外在网上申购前还需披露公募基金、社保和养老金三类长期投资者的报价情况。

Polyclonal antibodies have several advantages over monoclonal antibodies in various diagnostic settings. Polyclonal antibodies are often the most preferred choice in routine laboratory tests such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these antibodies does not require skilled professionals, and large batches can be produced as per client requirements. These antibodies can recognize multiple antigens on one epitope, and therefore can be utilized in the study of various diseases ranging from cancer to metabolic diseases. Denatured proteins are often detected with the use of polyclonal antibodies, which leads to an increase in demand for these antibodies.

The laboratory equipment market comprises equipment, services, and accessories that are useful for the purposes of creation, storage, and preservation of research samples. The laboratory equipment market has witnessed a considerable transformation over the past decade due to the high growth in research activities across the world. Sectors such as life science, biotechnology, and pharma have received significant support and impetus from both public and private sector investments.